Results 11 to 20 of about 96,616 (241)

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis [PDF]

JAMA Neurology, 2013
Given the high frequency of failure of first-line therapies, there is an urgent need for second-line treatment strategies for pediatric patients with multiple sclerosis (MS).To report the use of natalizumab in pediatric MS. Natalizumab, a humanized monoclonal antibody targeting α4 integrin, is effective against active relapsing-remitting MS in adults ...
Ruxandra-Iulia Miloš, Barbara Kornek, Antonios Bayas   +2 more
exaly   +3 more sources

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

Неврология, нейропсихиатрия, психосоматика, 2020
The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS ...
N. A. Totolyan, V. M. Alifirova, K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. N. Zakharova, D. S. Kasatkin, S. V. Kotov, A. I. Nilov, S. A. Sivertseva, A. A. Sokolova, N. N. Spirin, F. A. Khabirov, D. Paradnika   +14 more
doaj   +3 more sources

Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice

Неврология, нейропсихиатрия, психосоматика, 2020
Cladribine tablets are a new drug for the immune reconstitution therapy of highly active multiple sclerosis (HAMS). After discussing the characteristics of action of the drug in clinical trials, the authors give their own experience of its use in the ...
S. V. Petrov, O. V. Boyko, A. N. Boyko
doaj   +3 more sources

Impact of cladribine tablets on PROs in patients with MS: insights from the 1st interim analysis of the CLADFIT-MS study [PDF]

Frontiers in Neurology
BackgroundCladribine tablets are an oral short-course disease-modifying therapy (DMT) approved for the treatment of highly active relapsing multiple sclerosis (MS).
Giovanna Borriello, Giovanna Borriello, Clara Grazia Chisari, Clara Grazia Chisari, Davide Maimone, Francesca Matta, Massimiliano Mirabella, Massimiliano Mirabella, Damiano Paolicelli, Francesco Assogna, Sandro Caradonna, Francesco Patti, Francesco Patti   +12 more
doaj   +2 more sources

Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing–Remitting Multiple Sclerosis in Italy

Neurology and Therapy
Introduction Multiple sclerosis (MS) is a chronic autoimmune disease impacting the central nervous system. Individuals with highly active relapsing–remitting MS (HA-RRMS) frequently experience symptomatic episodes lasting more than 24 h, followed by a ...
Barbara Polistena, Anna Maria Provenzano, Caterina Rizzi, Elena Colombo, Roberto Bergamaschi   +4 more
doaj   +3 more sources

Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis

Неврология, нейропсихиатрия, психосоматика, 2020
Currently, special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance ...
K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, F. A. Khabirov, M. V. Shumilina   +12 more
doaj   +1 more source

Use of monoclonal antibodies in patients with multiple sclerosis in the practice of a neurologist

Медицинский совет, 2020
Multiple sclerosis (MS) ranks first for prevalence among diseases affecting the CNS white matter with 2.5 million cases estimated globally. InRussia, the number of cases is about 200 thousand.
N. Yu. Lashch
doaj   +1 more source

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab

Neuropsychiatric Disease and Treatment, 2015
Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the management of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus ...
Dubey D, Cano CA, Stuve O
openaire   +6 more sources

Therapy of highly active pediatric multiple sclerosis

Multiple Sclerosis Journal, 2017
Objective: Study aims were to determine the frequency of highly active disease in pediatric multiple sclerosis (MS), the response to natalizumab (NTZ) and fingolimod (FTY) treatment, and the impact of current treatment modalities on the clinical course ...
Huppke, Peter, Huppke, Brenda, Ellenberger, David, Rostasy, Kevin, Hummel, Hannah, Stark, Wiebke, Brück, Wolfgang, Gärtner, Jutta   +7 more
openaire   +3 more sources

Narrative review based on fingolimod therapy in pediatric MS

SAGE Open Medicine, 2023
The course of pediatric-onset multiple sclerosis and adult multiple sclerosis shows some clinical differences. The rate of having a second attack after the first clinical event is 80% in children and around 45% in adults but the time to the second event ...
Bilge Piri Cinar, Bahadır Konuskan, Banu Anlar, Serkan Ozakbas   +3 more
doaj   +1 more source